Alector completes enrollment in Phase 2 trial of Alzheimer’s candidate AL002

Alector (ALEC) has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease. Data from the trial are expected in Q4 2024. AL002 is being developed in collaboration with AbbVie (ABBV). INVOKE-2 is a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 clinical trial being conducted at multiple sites across 11 countries.